{"id":"chloroquine-sulfate","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Retinopathy (with prolonged use)"},{"rate":null,"effect":"Cardiomyopathy (rare, with high doses)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chloroquine works by concentrating in the digestive vacuoles of malaria parasites, where it binds to heme and prevents its detoxification into hemozoin. This causes toxic heme accumulation and parasite death. The drug also has immunomodulatory properties, including inhibition of toll-like receptor signaling and autophagy, which contribute to its anti-inflammatory effects.","oneSentence":"Chloroquine sulfate is an antimalarial agent that accumulates in parasitic food vacuoles and inhibits heme polymerization, leading to parasite death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:26.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria (treatment and prophylaxis)"},{"name":"Lupus erythematosus"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT01480154","phase":"PHASE1","title":"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-23","conditions":"Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7","enrollment":62},{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT06923592","phase":"PHASE3","title":"Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-05-12","conditions":"Malaria Vivax, Malaria Falciparum, Plasmodium Vivax","enrollment":19200},{"nctId":"NCT07343635","phase":"NA","title":"The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Erythematotelangiectatic Rosacea","enrollment":186},{"nctId":"NCT03822780","phase":"NA","title":"Hydroxychloroquin (HCQ) in chILD of Genetic Defect","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2017-07-01","conditions":"Surfactant Dysfunction","enrollment":25},{"nctId":"NCT04532346","phase":"EARLY_PHASE1","title":"Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2024-09-01","conditions":"Interstitial Lung Disease, Surfactant Dysfunction","enrollment":60},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT04527549","phase":"PHASE2","title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-06-01","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":5},{"nctId":"NCT05016297","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Sjogren's Syndrome","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-14","conditions":"Sjogren's Syndrome","enrollment":87},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":"Interstitial Lung Disease","enrollment":30},{"nctId":"NCT07430592","phase":"PHASE2","title":"This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"R. Kiplin Guy","startDate":"2026-03-20","conditions":"Malaria, Malaria Vivax, Radical Cure","enrollment":104},{"nctId":"NCT07436104","phase":"PHASE4","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01-01","conditions":"Hypertension (HTN), Diarrhea, Pneumonia","enrollment":72564},{"nctId":"NCT05799378","phase":"PHASE3","title":"Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-06-27","conditions":"Systemic Lupus Erythematosus","enrollment":330},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT04345692","phase":"PHASE3","title":"A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-03-26","conditions":"COVID-19","enrollment":17},{"nctId":"NCT02595346","phase":"PHASE2","title":"Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2016-05-17","conditions":"Antiphospholipid Syndrome (APS)","enrollment":25},{"nctId":"NCT06408298","phase":"EARLY_PHASE1","title":"HCQ in Resectable Localized Prostate Cancer","status":"RECRUITING","sponsor":"Lionel.D.Lewis, MD","startDate":"2026-01-06","conditions":"Resectable Localized Prostate Cancer","enrollment":20},{"nctId":"NCT03598595","phase":"PHASE1, PHASE2","title":"Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-28","conditions":"Recurrent Osteosarcoma, Refractory Osteosarcoma","enrollment":31},{"nctId":"NCT04201457","phase":"PHASE1, PHASE2","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2020-01-17","conditions":"Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1","enrollment":57},{"nctId":"NCT04524702","phase":"PHASE2","title":"Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-09-14","conditions":"Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":10},{"nctId":"NCT05842174","phase":"PHASE1, PHASE2","title":"Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-01","conditions":"Hepatocellular Carcinoma","enrollment":93},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT06076837","phase":"PHASE1","title":"The Seven Trial: Exploiting the Unfolded Protein Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2025-01-09","conditions":"Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic","enrollment":6},{"nctId":"NCT04481633","phase":"NA","title":"Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2020-09-09","conditions":"COVID-19","enrollment":552},{"nctId":"NCT06575647","phase":"PHASE4","title":"Vivax Elimination With Tafenoquine (VET) Study","status":"COMPLETED","sponsor":"Shoklo Malaria Research Unit","startDate":"2025-02-19","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax","enrollment":1242},{"nctId":"NCT06776445","phase":"PHASE1","title":"Efficacy and Safety of Different Dose Regimens of Gabapentin for Treating Erythema/Flushing in Rosacea: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2024-01-05","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":50},{"nctId":"NCT06971744","phase":"PHASE2","title":"Autophagy Maintenance (AUTOMAIN)","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-12-18","conditions":"Ovarian Cancer","enrollment":38},{"nctId":"NCT05843188","phase":"PHASE2","title":"Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-08-09","conditions":"Metastatic Colorectal Cancer","enrollment":155},{"nctId":"NCT02615938","phase":"PHASE2","title":"Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)","status":"TERMINATED","sponsor":"Matthias Griese","startDate":"2015-08-21","conditions":"Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease","enrollment":35},{"nctId":"NCT04344379","phase":"PHASE3","title":"Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-17","conditions":"SARS-CoV-2 Infection","enrollment":122},{"nctId":"NCT06083688","phase":"PHASE4","title":"Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-10-14","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":1000},{"nctId":"NCT07230028","phase":"PHASE4","title":"Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study.","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-03-01","conditions":"Lyme Borreliosis, Nervous System","enrollment":50},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT04132505","phase":"PHASE1","title":"Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":39},{"nctId":"NCT04787991","phase":"PHASE1","title":"Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Insight, LLC","startDate":"2021-08-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT05576896","phase":"PHASE2","title":"Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2022-10-10","conditions":"Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV","enrollment":43},{"nctId":"NCT00977470","phase":"PHASE2","title":"Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2009-10","conditions":"Non-small Cell Lung Cancer","enrollment":76},{"nctId":"NCT05036226","phase":"PHASE1, PHASE2","title":"COAST Therapy in Advanced Solid Tumors and Prostate Cancer","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-03-03","conditions":"Prostate Cancer Recurrent, Solid Tumor, Adult","enrollment":76},{"nctId":"NCT07190534","phase":"","title":"The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-11","conditions":"Frontal Fibrosing Alopecia, Cicatricial Alopecia","enrollment":50},{"nctId":"NCT04007562","phase":"","title":"Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-04","conditions":"LIPIN1 Deficiency","enrollment":""},{"nctId":"NCT05221320","phase":"PHASE2","title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","status":"TERMINATED","sponsor":"BioMed Valley Discoveries, Inc","startDate":"2022-05-26","conditions":"Tumor, Solid, Gastrointestinal Cancer","enrollment":47},{"nctId":"NCT04333654","phase":"PHASE1","title":"Hydroxychloroquine in Outpatient Adults With COVID-19","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-04-12","conditions":"Coronavirus Infection","enrollment":8},{"nctId":"NCT06652113","phase":"NA","title":"Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-11-15","conditions":"Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies","enrollment":796},{"nctId":"NCT03030118","phase":"PHASE2","title":"Study of Anti-Malarials in Incomplete Lupus Erythematosus","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2017-12-28","conditions":"Systemic Lupus Erythematosus","enrollment":187},{"nctId":"NCT05841758","phase":"PHASE4","title":"Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-07-30","conditions":"Sarcoidosis, Pulmonary","enrollment":140},{"nctId":"NCT04397328","phase":"PHASE3","title":"COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada","status":"WITHDRAWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-05-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":"Hepatocellular Cancer","enrollment":64},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT04669197","phase":"PHASE2","title":"Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2020-12-01","conditions":"Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":19},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT06666491","phase":"PHASE3","title":"An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Malaria, Vivax","enrollment":300},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT01506973","phase":"PHASE1, PHASE2","title":"A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2011-12","conditions":"Advanced Adenocarcinoma, Metastatic Adenocarcinoma","enrollment":119},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":"Malaria, Vivax","enrollment":1991},{"nctId":"NCT03377179","phase":"PHASE2","title":"A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2018-03-07","conditions":"Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar","enrollment":65},{"nctId":"NCT03032406","phase":"PHASE2","title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-01-23","conditions":"Breast Cancer Stage IIB","enrollment":53},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT07061717","phase":"PHASE3","title":"Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-07-01","conditions":"Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","enrollment":474},{"nctId":"NCT04464759","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","status":"RECRUITING","sponsor":"Ravi Amaravadi, MD","startDate":"2020-10-21","conditions":"Melanoma","enrollment":94},{"nctId":"NCT04354649","phase":"PHASE2","title":"Immune-Mediated Pathophysiology And Clinical Triage Program","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2021-09-16","conditions":"Arthritis, Arthralgia","enrollment":46},{"nctId":"NCT02603146","phase":"PHASE2","title":"Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-27","conditions":"Healthy Participants, Rheumatoid Arthritis (RA) Prevention","enrollment":144},{"nctId":"NCT06319560","phase":"NA","title":"Hydroxychloroquine in Type 2 Diabetes During Pregnancy","status":"RECRUITING","sponsor":"National University of Malaysia","startDate":"2024-03-24","conditions":"Diabetes in Pregnancy, Type 2 Diabetes","enrollment":56},{"nctId":"NCT04335084","phase":"PHASE2","title":"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"ProgenaBiome","startDate":"2020-06-22","conditions":"COVID-19, Coronavirus Infection, Sars-CoV2","enrollment":254},{"nctId":"NCT06350630","phase":"PHASE2","title":"Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-06","conditions":"IgA Nephropathy","enrollment":334},{"nctId":"NCT03979651","phase":"NA","title":"MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-10-15","conditions":"Metastatic NRAS Melanoma","enrollment":29},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax Malaria","enrollment":606},{"nctId":"NCT04379492","phase":"PHASE2","title":"A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-05-05","conditions":"COVID-19, COVID19, Sars-CoV2","enrollment":""},{"nctId":"NCT06939582","phase":"PHASE1, PHASE2","title":"Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis","status":"RECRUITING","sponsor":"Xingchen Peng","startDate":"2024-12-22","conditions":"Radiation-induced Oral Mucositis","enrollment":158},{"nctId":"NCT06020378","phase":"","title":"Hydroxychloroquine May be Beneficial for Preeclampsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-01-01","conditions":"Pre-Eclampsia","enrollment":462},{"nctId":"NCT05630989","phase":"","title":"A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy","status":"RECRUITING","sponsor":"Mandana Kamgar, MD","startDate":"2023-02-07","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":80},{"nctId":"NCT05365893","phase":"EARLY_PHASE1","title":"PHL Treatment in Pancreatic Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2021-10-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT03825289","phase":"PHASE1","title":"Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2019-01-18","conditions":"Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer","enrollment":25},{"nctId":"NCT05083780","phase":"PHASE1","title":"Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhoon Yoo","startDate":"2021-11-30","conditions":"Pancreatic Cancer","enrollment":40},{"nctId":"NCT04011410","phase":"PHASE2","title":"Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"Patrick Hensley","startDate":"2019-12-03","conditions":"Prostate Cancer Recurrent","enrollment":20},{"nctId":"NCT04523857","phase":"PHASE2","title":"ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-01","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT04735068","phase":"PHASE2","title":"Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-04-09","conditions":"Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors","enrollment":9},{"nctId":"NCT04841148","phase":"PHASE2","title":"Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-06-01","conditions":"Breast Cancer","enrollment":96},{"nctId":"NCT06862284","phase":"PHASE2","title":"Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-03-10","conditions":"Primary Sjögren's Syndrome (pSS)","enrollment":30},{"nctId":"NCT04363827","phase":"PHASE2","title":"Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2020-05-14","conditions":"COVID19, Hydroxychloroquine, Prophylaxis","enrollment":155},{"nctId":"NCT04704999","phase":"PHASE4","title":"Southeast Asia Dose Optimization of Tafenoquine","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2024-07-22","conditions":"Plasmodium Vivax Malaria","enrollment":700},{"nctId":"NCT00131703","phase":"PHASE3","title":"Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2003-03","conditions":"Malaria, Pregnancy","enrollment":900},{"nctId":"NCT04973566","phase":"PHASE1","title":"A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT04349371","phase":"PHASE2","title":"Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-04-21","conditions":"COVID, Coronavirus Infection","enrollment":5},{"nctId":"NCT05126147","phase":"PHASE4","title":"Hydroxychloroquine in Mild Graves' Orbitopathy","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-03-21","conditions":"Graves Ophthalmopathy","enrollment":108},{"nctId":"NCT04911816","phase":"PHASE1, PHASE2","title":"Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2021-07-16","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT03529396","phase":"PHASE2","title":"Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2018-07-20","conditions":"Vivax Malaria, G6PD Deficiency","enrollment":106},{"nctId":"NCT06389201","phase":"NA","title":"Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT03774472","phase":"PHASE1, PHASE2","title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":15},{"nctId":"NCT04386057","phase":"PHASE2","title":"LY3214996 +/- HCQ in Pancreatic Cancer","status":"COMPLETED","sponsor":"Kimberly Perez, MD","startDate":"2020-05-27","conditions":"Pancreatic Cancer, Advanced Cancer","enrollment":52},{"nctId":"NCT05119140","phase":"PHASE1, PHASE2","title":"Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-06-10","conditions":"Ulcerative Colitis (Disorder)","enrollment":3},{"nctId":"NCT04573153","phase":"PHASE2, PHASE3","title":"Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients","status":"TERMINATED","sponsor":"ScandiBio Therapeutics AB","startDate":"2020-09-21","conditions":"COVID-19","enrollment":100},{"nctId":"NCT06816810","phase":"PHASE2","title":"A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-03","conditions":"Parkinson&Amp;#39;s Disease","enrollment":40},{"nctId":"NCT03636152","phase":"PHASE2","title":"Management of Cardiovascular Disease in Kidney Disease (MaCK) Study","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-12-14","conditions":"Chronic Kidney Disease, Cardiovascular Disease, Inflammation","enrollment":100},{"nctId":"NCT04397679","phase":"PHASE1","title":"Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2021-08-12","conditions":"Glioblastoma, Gliosarcoma","enrollment":2},{"nctId":"NCT06768294","phase":"PHASE2","title":"Baricitinib in CPPD - the BAPTIST Study","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2025-01","conditions":"Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis","enrollment":32},{"nctId":"NCT04385264","phase":"PHASE2, PHASE3","title":"#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19","status":"WITHDRAWN","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2022-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05287321","phase":"PHASE3","title":"The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia","status":"RECRUITING","sponsor":"Yoo-min Kim","startDate":"2022-05-31","conditions":"Preeclampsia","enrollment":58},{"nctId":"NCT06739759","phase":"NA","title":"Ovarian Hyperstimulation Syndrome Prevention","status":"RECRUITING","sponsor":"Aljazeera Hospital","startDate":"2024-11-17","conditions":"Ovarian Hyper Stimulation Syndrome (OHSS)","enrollment":300},{"nctId":"NCT04214418","phase":"PHASE1, PHASE2","title":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-02-12","conditions":"Gastrointestinal Cancer","enrollment":27},{"nctId":"NCT03503058","phase":"PHASE2","title":"Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2022-05-07","conditions":"Malaria","enrollment":345}],"_emaApprovals":[],"_faersSignals":[{"count":16,"reaction":"OFF LABEL USE"},{"count":12,"reaction":"DRUG INEFFECTIVE"},{"count":10,"reaction":"CONDITION AGGRAVATED"},{"count":9,"reaction":"TREATMENT FAILURE"},{"count":8,"reaction":"RHEUMATOID ARTHRITIS"},{"count":7,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":6,"reaction":"PAIN"},{"count":5,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":5,"reaction":"ARTHRITIS"},{"count":5,"reaction":"COVID-19"}],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aralen GENERIC NAME(S): Chloroquine Phosphate","NIVAQUINE"],"phase":"marketed","status":"active","brandName":"Chloroquine Sulfate","genericName":"Chloroquine Sulfate","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chloroquine sulfate is an antimalarial agent that accumulates in parasitic food vacuoles and inhibits heme polymerization, leading to parasite death. Used for Malaria (treatment and prophylaxis), Lupus erythematosus, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}